Hepatitis B Surface Antigen Decline during Sofosbuvir and Ribavirin Therapy in Hepatitis B Inactive Carriers Who Were Co-infected with Hepatitis C

Direct-acting antiviral (DAA) therapy carries a potential risk of inducing hepatitis B virus (HBV) reactivation. However, the HBV kinetics during and after DAA therapy in patients co-infected with hepatitis C virus (HCV) and HBV remain unknown. We retrospectively evaluated the HBV kinetics during an...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Shunsuke, Tsuzura, Hironori, Kita, Yuji, Ikeda, Yuji, Kabemura, Daishi, Sato, Sho, Amano, Nozomi, Yatagai, Noboru, Murata, Ayato, Shimada, Yuji, Genda, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666226/
https://www.ncbi.nlm.nih.gov/pubmed/33994440
http://dx.doi.org/10.2169/internalmedicine.7337-21
_version_ 1784614161631674368
author Sato, Shunsuke
Tsuzura, Hironori
Kita, Yuji
Ikeda, Yuji
Kabemura, Daishi
Sato, Sho
Amano, Nozomi
Yatagai, Noboru
Murata, Ayato
Shimada, Yuji
Genda, Takuya
author_facet Sato, Shunsuke
Tsuzura, Hironori
Kita, Yuji
Ikeda, Yuji
Kabemura, Daishi
Sato, Sho
Amano, Nozomi
Yatagai, Noboru
Murata, Ayato
Shimada, Yuji
Genda, Takuya
author_sort Sato, Shunsuke
collection PubMed
description Direct-acting antiviral (DAA) therapy carries a potential risk of inducing hepatitis B virus (HBV) reactivation. However, the HBV kinetics during and after DAA therapy in patients co-infected with hepatitis C virus (HCV) and HBV remain unknown. We retrospectively evaluated the HBV kinetics during and after sofosbuvir/ribavirin therapy in four HBV inactive carriers co-infected with HCV. HCV was eradicated in all patients. Changes in HBV-DNA levels during treatment differed among patients. The hepatitis B surface antigen (HBsAg) levels uniformly decreased (mean -0.530 logIU/mL) by the end of treatment and returned to near the baseline in all patients. Sofosbuvir/ribavirin therapy thus demonstrated a suppressive effect on HBsAg.
format Online
Article
Text
id pubmed-8666226
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-86662262021-12-28 Hepatitis B Surface Antigen Decline during Sofosbuvir and Ribavirin Therapy in Hepatitis B Inactive Carriers Who Were Co-infected with Hepatitis C Sato, Shunsuke Tsuzura, Hironori Kita, Yuji Ikeda, Yuji Kabemura, Daishi Sato, Sho Amano, Nozomi Yatagai, Noboru Murata, Ayato Shimada, Yuji Genda, Takuya Intern Med Case Report Direct-acting antiviral (DAA) therapy carries a potential risk of inducing hepatitis B virus (HBV) reactivation. However, the HBV kinetics during and after DAA therapy in patients co-infected with hepatitis C virus (HCV) and HBV remain unknown. We retrospectively evaluated the HBV kinetics during and after sofosbuvir/ribavirin therapy in four HBV inactive carriers co-infected with HCV. HCV was eradicated in all patients. Changes in HBV-DNA levels during treatment differed among patients. The hepatitis B surface antigen (HBsAg) levels uniformly decreased (mean -0.530 logIU/mL) by the end of treatment and returned to near the baseline in all patients. Sofosbuvir/ribavirin therapy thus demonstrated a suppressive effect on HBsAg. The Japanese Society of Internal Medicine 2021-05-14 2021-11-15 /pmc/articles/PMC8666226/ /pubmed/33994440 http://dx.doi.org/10.2169/internalmedicine.7337-21 Text en Copyright © 2021 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Sato, Shunsuke
Tsuzura, Hironori
Kita, Yuji
Ikeda, Yuji
Kabemura, Daishi
Sato, Sho
Amano, Nozomi
Yatagai, Noboru
Murata, Ayato
Shimada, Yuji
Genda, Takuya
Hepatitis B Surface Antigen Decline during Sofosbuvir and Ribavirin Therapy in Hepatitis B Inactive Carriers Who Were Co-infected with Hepatitis C
title Hepatitis B Surface Antigen Decline during Sofosbuvir and Ribavirin Therapy in Hepatitis B Inactive Carriers Who Were Co-infected with Hepatitis C
title_full Hepatitis B Surface Antigen Decline during Sofosbuvir and Ribavirin Therapy in Hepatitis B Inactive Carriers Who Were Co-infected with Hepatitis C
title_fullStr Hepatitis B Surface Antigen Decline during Sofosbuvir and Ribavirin Therapy in Hepatitis B Inactive Carriers Who Were Co-infected with Hepatitis C
title_full_unstemmed Hepatitis B Surface Antigen Decline during Sofosbuvir and Ribavirin Therapy in Hepatitis B Inactive Carriers Who Were Co-infected with Hepatitis C
title_short Hepatitis B Surface Antigen Decline during Sofosbuvir and Ribavirin Therapy in Hepatitis B Inactive Carriers Who Were Co-infected with Hepatitis C
title_sort hepatitis b surface antigen decline during sofosbuvir and ribavirin therapy in hepatitis b inactive carriers who were co-infected with hepatitis c
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666226/
https://www.ncbi.nlm.nih.gov/pubmed/33994440
http://dx.doi.org/10.2169/internalmedicine.7337-21
work_keys_str_mv AT satoshunsuke hepatitisbsurfaceantigendeclineduringsofosbuvirandribavirintherapyinhepatitisbinactivecarrierswhowerecoinfectedwithhepatitisc
AT tsuzurahironori hepatitisbsurfaceantigendeclineduringsofosbuvirandribavirintherapyinhepatitisbinactivecarrierswhowerecoinfectedwithhepatitisc
AT kitayuji hepatitisbsurfaceantigendeclineduringsofosbuvirandribavirintherapyinhepatitisbinactivecarrierswhowerecoinfectedwithhepatitisc
AT ikedayuji hepatitisbsurfaceantigendeclineduringsofosbuvirandribavirintherapyinhepatitisbinactivecarrierswhowerecoinfectedwithhepatitisc
AT kabemuradaishi hepatitisbsurfaceantigendeclineduringsofosbuvirandribavirintherapyinhepatitisbinactivecarrierswhowerecoinfectedwithhepatitisc
AT satosho hepatitisbsurfaceantigendeclineduringsofosbuvirandribavirintherapyinhepatitisbinactivecarrierswhowerecoinfectedwithhepatitisc
AT amanonozomi hepatitisbsurfaceantigendeclineduringsofosbuvirandribavirintherapyinhepatitisbinactivecarrierswhowerecoinfectedwithhepatitisc
AT yatagainoboru hepatitisbsurfaceantigendeclineduringsofosbuvirandribavirintherapyinhepatitisbinactivecarrierswhowerecoinfectedwithhepatitisc
AT murataayato hepatitisbsurfaceantigendeclineduringsofosbuvirandribavirintherapyinhepatitisbinactivecarrierswhowerecoinfectedwithhepatitisc
AT shimadayuji hepatitisbsurfaceantigendeclineduringsofosbuvirandribavirintherapyinhepatitisbinactivecarrierswhowerecoinfectedwithhepatitisc
AT gendatakuya hepatitisbsurfaceantigendeclineduringsofosbuvirandribavirintherapyinhepatitisbinactivecarrierswhowerecoinfectedwithhepatitisc

Ejemplares similares